Eliem Therapeutics company info

What does Eliem Therapeutics do?
Eliem Therapeutics (NASDAQ:ELYM) is a biotechnology firm focused on developing therapies for neurologic and psychiatric disorders. Their projects aim to address the significant unmet medical needs within these conditions, leveraging advanced understanding of nerve signaling pathways and brain circuitry. The company is engaged in a range of research and development efforts, with the objective to bring innovative, effective treatments to patients suffering from epilepsy, chronic pain, and a variety of mental health conditions. Through a combination of proprietary technology and strategic partnerships, Eliem Therapeutics works to advance its pipeline of novel candidates towards clinical trials and eventual commercialization, aspiring to improve the quality of life for individuals affected by these challenging disorders.
Eliem Therapeutics company media
Company Snapshot

Is Eliem Therapeutics a public or private company?


How many people does Eliem Therapeutics employ?


What sector is Eliem Therapeutics in?

pie chart
Health Care

Where is the head office for Eliem Therapeutics?

location pin
Head Office
Wilmington, United States

What year was Eliem Therapeutics founded?

founded flag
Year Founded
What does Eliem Therapeutics specialise in?
/Neurological Treatments /Drug Development /Chronic Pain Therapies /Neuropsychiatric Disorders /Scientific Research /Clinical Trials

What are the products and/or services of Eliem Therapeutics?

Overview of Eliem Therapeutics offerings
ETX-810, a novel peptide for treating chronic pain.
ETX-155, a hormone modulator aimed at depression and epilepsy.
Non-opioid pain management initiatives.
Advanced therapies for neurological disorders.
Research on sustained release formulations.
Collaborations for drug discovery and development.

Who is in the executive team of Eliem Therapeutics?

Eliem Therapeutics leadership team
  • Dr. Andrew  Levin M.D., Ph.D.
    Dr. Andrew Levin M.D., Ph.D.
    Principal Financial Officer & Executive Chairman
  • Dr. Valerie  Morisset Ph.D.
    Dr. Valerie Morisset Ph.D.
    Chief Scientific Officer and Executive VP of Research & Development
  • Ms. Emily  Pimblett
    Ms. Emily Pimblett
    Principal Accounting Officer
  • Ms. Jo  Palmer-Phillips Ph.D.
    Ms. Jo Palmer-Phillips Ph.D.
    Chief Development Officer